Literature DB >> 12202545

Cavitary pneumonia in an AIDS patient caused by an unusual Bordetella bronchiseptica variant producing reduced amounts of pertactin and other major antigens.

Benito Lorenzo-Pajuelo1, José Luis Villanueva, Juan Rodríguez-Cuesta, Nuria Vergara-Irigaray, Máximo Bernabeu-Wittel, Andrés Garcia-Curiel, Guillermo Martínez de Tejada.   

Abstract

Although Bordetella bronchiseptica can infect and colonize immunocompromised humans, its role as a primary pathogen in pneumonia and other respiratory processes affecting those patients remains controversial. A case of cavitary pneumonia caused by B. bronchiseptica in an AIDS patient is presented, and the basis of the seemingly enhanced pathogenic potential of this isolate (designated 814) is investigated. B. bronchiseptica was the only microorganism recovered from sputum, bronchoalveolar lavage fluid, and samples taken through the protected brush catheter. Unlike previous work reporting the involvement of B. bronchiseptica in cases of pneumonia, antibiotic treatment selected on the basis of in vitro antibacterial activity resulted in clearance of the infection and resolution of the pulmonary infiltrate. Although isolate 814 produced reduced amounts of several major antigens including at least one Bvg-activated factor (pertactin), the molecular basis of this deficiency was found to be BvgAS independent since the defect persisted after the bvgAS locus of isolate 814 was replaced with a wild-type bvgAS allele. Despite its prominent phenotype, isolate 814 displayed only a modest yet a significant deficiency in its ability to colonize the respiratory tracts of immunocompetent rats at an early time point. Interestingly, the antibody response elicited by isolate 814 in these animals was almost undetectable. We propose that isolate 814 may be more virulent in immunocompromised patients due, at least in part, to its innate ability to produce low amounts of immunogenic factors which may be required at only normal levels for the interaction of this pathogen with its immunocompetent natural hosts.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12202545      PMCID: PMC130797          DOI: 10.1128/JCM.40.9.3146-3154.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

1.  [Bordetella bronchiseptica infection in a Senegalese HIV positive patient: carrier state or illness?].

Authors:  P Hovette; P Colbacchini; P Camara; C Aubron; M C N'Dir; T Passeron
Journal:  Presse Med       Date:  2001-05-19       Impact factor: 1.228

2.  Recovery of Bordetella bronchiseptica from patients with AIDS.

Authors:  V L Ng; J M Boggs; M K York; J A Golden; H Hollander; W K Hadley
Journal:  Clin Infect Dis       Date:  1992-08       Impact factor: 9.079

3.  Bordetella bronchiseptica recurrent bacteraemia in the setting of a patient with AIDS and indwelling Broviac catheter.

Authors:  M N Qureshi; J Lederman; E Neibart; E J Bottone
Journal:  Int J STD AIDS       Date:  1992 Jul-Aug       Impact factor: 1.359

4.  Pneumonia due to Bordetella bronchiseptica in a patient with AIDS.

Authors:  C Amador; E Chiner; J L Calpe; V Ortiz de la Table; C Martinez; F Pasquau
Journal:  Rev Infect Dis       Date:  1991 Jul-Aug

5.  Pneumonia due to Bordetella bronchiseptica in a patient with AIDS.

Authors:  G R Decker; J P Lavelle; P N Kumar; P F Pierce
Journal:  Rev Infect Dis       Date:  1991 Nov-Dec

6.  A simple chemically defined medium for the production of phase I Bordetella pertussis.

Authors:  D W Stainer; M J Scholte
Journal:  J Gen Microbiol       Date:  1970-10

7.  Identification of a 69-kilodalton nonfimbrial protein as an agglutinogen of Bordetella pertussis.

Authors:  M J Brennan; Z M Li; J L Cowell; M E Bisher; A C Steven; P Novotny; C R Manclark
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

8.  Identification and characterization of a protective immunodominant B cell epitope of pertactin (P.69) from Bordetella pertussis.

Authors:  I G Charles; J L Li; M Roberts; K Beesley; M Romanos; D J Pickard; M Francis; D Campbell; G Dougan; M J Brennan
Journal:  Eur J Immunol       Date:  1991-05       Impact factor: 5.532

9.  In vitro and in vivo characterization of a Bordetella bronchiseptica mutant strain with a deep rough lipopolysaccharide structure.

Authors:  Federico Sisti; Julieta Fernández; María Eugenia Rodríguez; Antonio Lagares; Nicole Guiso; Daniela Flavia Hozbor
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

10.  The bvgAS locus negatively controls motility and synthesis of flagella in Bordetella bronchiseptica.

Authors:  B J Akerley; D M Monack; S Falkow; J F Miller
Journal:  J Bacteriol       Date:  1992-02       Impact factor: 3.490

View more
  11 in total

1.  External quality assessment for molecular detection of Bordetella pertussis in European laboratories.

Authors:  G Muyldermans; O Soetens; M Antoine; S Bruisten; B Vincart; F Doucet-Populaire; N K Fry; P Olcén; J M Scheftel; J M Senterre; A van der Zee; M Riffelmann; D Piérard; S Lauwers
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

Review 2.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

3.  Chronic cough and cystic lung disease caused by Bordetella bronchiseptica in a patient with AIDS.

Authors:  Muhammad Sameed; Scott Sullivan; Ellen T Marciniak; Janaki Deepak
Journal:  BMJ Case Rep       Date:  2019-04-16

4.  Zoonotic Bacterial Respiratory Infections Associated With Cats and Dogs: A Case Series and Literature Review.

Authors:  Lauren E Rybolt; Suhel Sabunwala; John N Greene
Journal:  Cureus       Date:  2022-04-23

5.  Evaluation of real-time PCR for detection of and discrimination between Bordetella pertussis, Bordetella parapertussis, and Bordetella holmesii for clinical diagnosis.

Authors:  Kate E Templeton; Sitha A Scheltinga; Anneke van der Zee; Bram M W Diederen; Alida M van Kruijssen; Herman Goossens; Ed Kuijper; Eric C J Claas
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

6.  Kitten-transmitted Bordetella bronchiseptica infection in a patient receiving temozolomide for glioblastoma.

Authors:  Gil Redelman-Sidi; Christian Grommes; Genovefa Papanicolaou
Journal:  J Neurooncol       Date:  2010-07-30       Impact factor: 4.506

7.  Bordetella bronchiseptica pneumonia in a patient with lung cancer; a case report of a rare infection.

Authors:  Manlio Monti; Danila Diano; Francesco Allegrini; Angelo Delmonte; Valentina Fausti; Paola Cravero; Giulia Marcantognini; Giovanni Luca Frassineti
Journal:  BMC Infect Dis       Date:  2017-09-25       Impact factor: 3.090

8.  Bordetella pertussis infection or vaccination substantially protects mice against B. bronchiseptica infection.

Authors:  Elizabeth M Goebel; Xuqing Zhang; Eric T Harvill
Journal:  PLoS One       Date:  2009-08-26       Impact factor: 3.240

9.  Bordetella bronchiseptica pneumonia in a man with acquired immunodeficiency syndrome: a case report.

Authors:  Michal Galeziok; Ingram Roberts; Jo-Anne Passalacqua
Journal:  J Med Case Rep       Date:  2009-10-15

10.  Bordetella bronchiseptica in the immunosuppressed population - a case series and review.

Authors:  Abraham T Yacoub; Mitsuya Katayama; Joann Tran; Ronit Zadikany; Manasa Kandula; John Greene
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-04-07       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.